Val
—
Gro
—
Qua
—
Mom
—
Sta
—
Cap—
P/S3.32
P/E—
Fwd P/E12.40
PEG0.57
52W— – —
RSI—
Target$72.31 (+57.1%)
Beta0.58
Div—
Loading chart…
RSI (14)
Loading patterns…
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
52-Week Range
52W Low
—
52W High
Position in Range
—
RSI (14)
0 · Oversold
RSI 54
Overbought · 100
Signal
Neutral
EMA Price Levels
Volume Analysis
Momentum Dashboard
Trend Strength
Detected Patterns
0Bullish
7Bearish
0Neutral
▼ Bear Flag — Breakdown after -10% pole — bearish continuation
▼ Bear Flag — Breakdown after -12% pole — bearish continuation
▼ Double Top — Two peaks ~$58.34 — bearish reversal confirmed
▼ Bear Flag — Breakdown after -14% pole — bearish continuation
▼ Bear Flag — Breakdown after -15% pole — bearish continuation
▼ Bear Flag — Breakdown after -22% pole — bearish continuation
▼ Bear Flag — Breakdown after -9% pole — bearish continuation
View overlays on the price chart via Chart tab → Pattern Overlays.
EPS — History & Forecast
Estimate
Beat
Miss
Forecast
Loading…
Revenue — History & Forecast
Revenue
Forecast
Loading…
EPS Beat Rate
100%
8/8 quarters
Wall Street Consensus
STRONG BUY
BuyHoldSell
Price Target Range
$72.31
+57.1% upside
Low $55
—
High $106
Consensus
Current price
Wall Street Analyst Ratings
| Firm | Rating | Change | Action | Date |
|---|---|---|---|---|
| BTIG | Buy | — | ↔ Maintain | 2026-07-29 |
| Oppenheimer | Outperform | — | ↔ Maintain | 2026-07-27 |
| Truist Securities | Buy | — | ↔ Maintain | 2026-07-16 |
| Mizuho | Outperform | — | ↔ Maintain | 2026-07-15 |
| RBC Capital | Outperform | — | ↔ Maintain | 2026-07-13 |
| Needham | Buy | — | ↔ Maintain | 2026-07-08 |
| Evercore ISI Group | Outperform | — | ↔ Maintain | 2026-07-06 |
| Stifel | Buy | — | ↔ Maintain | 2026-06-25 |
| Jefferies | Buy | — | ↔ Maintain | 2026-06-24 |
| Canaccord Genuity | Buy | — | ↔ Maintain | 2026-06-01 |
| Wolfe Research | Peer Perform | Outperform → Peer Perform | ▼ Downgrade | 2026-05-29 |
| Citigroup | Buy | — | ↔ Maintain | 2026-05-28 |
| Leerink Partners | Outperform | — | ↔ Maintain | 2026-05-28 |
| Barclays | Overweight | — | ↔ Maintain | 2026-05-28 |
| Wells Fargo | Equal-Weight | Overweight → Equal-Weight | ▼ Downgrade | 2026-05-28 |
| Baird | Outperform | — | ↔ Maintain | 2026-05-19 |
| B of A Securities | Buy | — | ↔ Maintain | 2026-05-18 |
| Goldman Sachs | Buy | — | ↔ Maintain | 2026-04-23 |
| Raymond James | Outperform | Strong Buy → Outperform | ▼ Downgrade | 2026-03-30 |
| UBS | Buy | — | ↔ Maintain | 2026-03-17 |
| JP Morgan | Overweight | — | ↔ Maintain | 2026-02-05 |
| TD Cowen | Buy | — | ↔ Maintain | 2026-02-05 |
| Morgan Stanley | Overweight | — | ↔ Maintain | 2026-02-05 |
BTIG
2026-07-29
Buy
↔ Maintain
Oppenheimer
2026-07-27
Outperform
↔ Maintain
Truist Securities
2026-07-16
Buy
↔ Maintain
Mizuho
2026-07-15
Outperform
↔ Maintain
RBC Capital
2026-07-13
Outperform
↔ Maintain
Needham
2026-07-08
Buy
↔ Maintain
Evercore ISI Group
2026-07-06
Outperform
↔ Maintain
Stifel
2026-06-25
Buy
↔ Maintain
Jefferies
2026-06-24
Buy
↔ Maintain
Canaccord Genuity
2026-06-01
Buy
↔ Maintain
Wolfe Research
2026-05-29
Peer Perform
(from Outperform)
▼ Downgrade
Citigroup
2026-05-28
Buy
↔ Maintain
Leerink Partners
2026-05-28
Outperform
↔ Maintain
Barclays
2026-05-28
Overweight
↔ Maintain
Wells Fargo
2026-05-28
Equal-Weight
(from Overweight)
▼ Downgrade
Baird
2026-05-19
Outperform
↔ Maintain
B of A Securities
2026-05-18
Buy
↔ Maintain
Goldman Sachs
2026-04-23
Buy
↔ Maintain
Raymond James
2026-03-30
Outperform
(from Strong Buy)
▼ Downgrade
UBS
2026-03-17
Buy
↔ Maintain
JP Morgan
2026-02-05
Overweight
↔ Maintain
TD Cowen
2026-02-05
Buy
↔ Maintain
Morgan Stanley
2026-02-05
Overweight
↔ Maintain
Profitability
Gross Margin
68.94%TTM
Op. Margin
20.60%TTM
ROE
14.66%TTM
Rev. Growth
11.60%YoY
Free Cash Flow
2.81BTTM
FCF Yield
—TTM
Balance Sheet
Debt / Equity
42.25MRQ
Current Ratio
1.90MRQ
Cash
1.45BMRQ
Total Debt
11.03BMRQ
Net Debt
—MRQ
How BSX Makes Its Money
Cash Flow Breakdown
Quarterly Metrics
| Quarter | Revenue | Rev YoY | Gross Profit | Op. Income | Net Income | Net YoY | Gross % | Op % | Net % |
|---|
Full Key Statistics
Valuation
| Market Cap | 68.43B |
| Enterprise Value | 78.28B |
| Trailing P/E | 19.26 |
| Forward P/E | 12.40 |
| PEG Ratio (5yr) | 0.57 |
| Price/Sales (ttm) | 3.32 |
| Price/Book (mrq) | 2.65 |
| EV/Revenue | 3.80 |
| EV/EBITDA | 14.23 |
Share Statistics
| Avg Vol (3m) | 20.37M |
| Shares Outstanding | 1.49B |
| Float | 1.48B |
| % Held by Insiders | 0.23% |
| % Held by Institutions | 93.84% |
| Short Ratio | 1.42 |
| Short % of Float | 1.90% |
Profitability
| Gross Margin | 68.94% |
| Operating Margin (ttm) | 20.60% |
| Profit Margin | 17.29% |
| Return on Assets (ttm) | 6.07% |
| Return on Equity (ttm) | 14.66% |
Income Statement
| Revenue (ttm) | 20.61B |
| Revenue Growth (yoy) | 11.60% |
| Gross Profit (ttm) | 14.21B |
| EBITDA | 5.50B |
| Net Income (ttm) | 3.56B |
| Diluted EPS (ttm) | 2.39 |
| EPS Growth (yoy) | 100.00% |
Balance Sheet
| Total Cash (mrq) | 1.45B |
| Total Debt (mrq) | 11.03B |
| Debt / Equity (mrq) | 42.25 |
| Current Ratio (mrq) | 1.90 |
| Book Value / Share | 17.40 |
| Operating CF (ttm) | 4.34B |
| Free Cash Flow (ttm) | 2.81B |
Trading & Dividends
| Beta (5Y) | 0.58 |
| 50-Day MA | 47.14 |
| 200-Day MA | 73.92 |
| Fwd Dividend Yield | N/A |
| Payout Ratio | 0.00% |
Ownership Breakdown
Institutional 93.84%
Insider 0.23%
Public 5.9%
Short Interest
1.90% of float
Low
Institutional 13F Holdings
Famous investors who disclosed a position in BSX in their latest SEC 13F filing.
Loading…
Insider Transactions
| Date | Insider | Role | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-01 | MONSON JONATHAN R | Chief Financial Officer | 2,087 | — | |
| 2026-05-28 | MAHONEY MICHAEL F | Chief Executive Officer | Stock Gift at price 0.00 per share. | 386,755 | — |
| 2026-05-20 | LUDWIG EDWARD J. | Director | Purchase at price 56.68 per share. | 3,580 | $202,914 |
| 2026-05-20 | HABIGER DAVID C | Director | Purchase at price 55.92 - 56.95 per share. | 4,450 | $251,098 |
| 2026-05-20 | PEGUS CHERYL | Director | Purchase at price 56.49 per share. | 1,770 | $99,987 |
| 2026-05-07 | MEGA JESSICA L M.D. | Director | Stock Award(Grant) at price 0.00 per share. | 3,800 | — |
| 2026-05-07 | MORANO SUSAN E. | Director | Stock Award(Grant) at price 0.00 per share. | 5,081 | — |
| 2026-05-07 | WEBER CHRISTOPHE PIERRE | Director | Stock Award(Grant) at price 0.00 per share. | 2,907 | — |
| 2026-05-07 | LUDWIG EDWARD J. | Director | Stock Award(Grant) at price 0.00 per share. | 3,800 | — |
| 2026-05-07 | ZANE ELLEN M | Director | Stock Award(Grant) at price 0.00 per share. | 3,800 | — |
| 2026-05-07 | WICHMANN DAVID S | Director | Stock Award(Grant) at price 0.00 per share. | 3,800 | — |
| 2026-05-07 | HABIGER DAVID C | Director | Stock Award(Grant) at price 0.00 per share. | 3,800 | — |
| 2026-05-01 | BUTCHER ARTHUR C | Officer | 2,102 | — | |
| 2026-05-01 | O'CONNOR PADRAIG ANDREW | Officer | 1,802 | — | |
| 2026-03-02 | MORANO SUSAN E. | Director | Stock Award(Grant) at price 0.00 per share. | 24 | — |
| 2026-03-02 | WEBER CHRISTOPHE PIERRE | Director | Stock Award(Grant) at price 0.00 per share. | 879 | — |
| 2026-02-27 | WOODWORTH EMILY | Officer | 838 | — | |
| 2026-02-13 | FITZGERALD JOSEPH MICHAEL | Officer | 11,119 | — | |
| 2026-02-13 | MAHONEY MICHAEL F | Chief Executive Officer | 41,621 | — | |
| 2026-02-13 | BUTCHER ARTHUR C | Officer | 7,956 | — | |
| 2026-02-13 | MONSON JONATHAN R | Chief Financial Officer | 3,814 | — | |
| 2026-02-13 | BROWN VANCE R | General Counsel | 4,808 | — | |
| 2026-02-13 | WOODWORTH EMILY | Officer | 2,711 | — | |
| 2026-02-13 | O'SULLIVAN MIRIAM | Officer | 2,702 | — | |
| 2026-02-13 | O'CONNOR PADRAIG ANDREW | Officer | 2,595 | — |
MONSON JONATHAN R
Chief Financial Officer
2026-07-01
2,087 sh
—
MAHONEY MICHAEL F
Chief Executive Officer
Stock Gift at price 0.00 per share.
2026-05-28
386,755 sh
—
LUDWIG EDWARD J.
Director
Purchase at price 56.68 per share.
2026-05-20
3,580 sh
$202,914
HABIGER DAVID C
Director
Purchase at price 55.92 - 56.95 per share.
2026-05-20
4,450 sh
$251,098
PEGUS CHERYL
Director
Purchase at price 56.49 per share.
2026-05-20
1,770 sh
$99,987
MEGA JESSICA L M.D.
Director
Stock Award(Grant) at price 0.00 per share.
2026-05-07
3,800 sh
—
MORANO SUSAN E.
Director
Stock Award(Grant) at price 0.00 per share.
2026-05-07
5,081 sh
—
WEBER CHRISTOPHE PIERRE
Director
Stock Award(Grant) at price 0.00 per share.
2026-05-07
2,907 sh
—
LUDWIG EDWARD J.
Director
Stock Award(Grant) at price 0.00 per share.
2026-05-07
3,800 sh
—
ZANE ELLEN M
Director
Stock Award(Grant) at price 0.00 per share.
2026-05-07
3,800 sh
—
WICHMANN DAVID S
Director
Stock Award(Grant) at price 0.00 per share.
2026-05-07
3,800 sh
—
HABIGER DAVID C
Director
Stock Award(Grant) at price 0.00 per share.
2026-05-07
3,800 sh
—
BUTCHER ARTHUR C
Officer
2026-05-01
2,102 sh
—
O'CONNOR PADRAIG ANDREW
Officer
2026-05-01
1,802 sh
—
MORANO SUSAN E.
Director
Stock Award(Grant) at price 0.00 per share.
2026-03-02
24 sh
—
WEBER CHRISTOPHE PIERRE
Director
Stock Award(Grant) at price 0.00 per share.
2026-03-02
879 sh
—
WOODWORTH EMILY
Officer
2026-02-27
838 sh
—
FITZGERALD JOSEPH MICHAEL
Officer
2026-02-13
11,119 sh
—
MAHONEY MICHAEL F
Chief Executive Officer
2026-02-13
41,621 sh
—
BUTCHER ARTHUR C
Officer
2026-02-13
7,956 sh
—
MONSON JONATHAN R
Chief Financial Officer
2026-02-13
3,814 sh
—
BROWN VANCE R
General Counsel
2026-02-13
4,808 sh
—
WOODWORTH EMILY
Officer
2026-02-13
2,711 sh
—
O'SULLIVAN MIRIAM
Officer
2026-02-13
2,702 sh
—
O'CONNOR PADRAIG ANDREW
Officer
2026-02-13
2,595 sh
—